Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330482 | 0.91 | GAA (0.77) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2334417 | 0.90 | GAA (0.59) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2335153 | 0.86 | GAA (0.79) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2332683 | 0.85 | CYP3A4 (0.76) | CYP3A4GAASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2334861 | 0.83 | CYP3A4 (0.68) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2337751 | 0.83 | GAA (0.74) | CYP3A4GAASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL2334030 | 0.81 | GAA (0.82) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2330237 | 0.79 | GAA (0.62) | CYP3A4GAAALDH1A1KDM4ETSHR | |
| SCHEMBL2336448 | 0.78 | GAA (1.00) | CYP3A4GAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL14424953 | 0.76 | GAA (0.71) | CYP3A4GAAALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | claimed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| EP-2358682-A2 | ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010055164-A2 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | CYP3A4 722/4885GAA 2348/4885SMN1; SMN2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.